[The bioequivalence of two nifedipine sustained-release formulations after single administration in steady state].
Investigations into the Bioequivalence of Two Nifedipine Controlled-release Formulations after Single Application and in Steady State. The bioequivalence of nifedipine (CAS 21829-25-4) in controlled-release formulation (Corinfar retard dragees) was tested versus a reference preparation in 22 subjects in a cross-over design after the first dose and in steady state. Compared to the reference, the preparations tested were found to have a relative bioavailability of 0.86 and 0.95, respectively. The bioavailability parameters of the preparations tested did not differ from each other. In particular, the fluctuation indices were noted to be highly similar. In view of the marked prolonged-action effect, a twice-per-day application is possible for the majority of the patients.
Meyer
F P
FP
Institut für Klinische Pharmakologie, Medizinischen Akademie, Magdeburg.
Banditt
P
P
D000328:Adult; D001682:Biological Availability; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency
D003692:Delayed-Action Preparations; D009543:Nifedipine
Untersuchungen zur Bioäquivalenz von zwei Nifedipin-Retardformulierungen nach einmaliger Applikation und im Steady-State.